Deferred Tax Assets, Valuation Allowance of Coherus Oncology, Inc. from 31 Dec 2013 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Coherus Oncology, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2013 to 31 Dec 2025.
  • Coherus Oncology, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $368,124,000, a 11% decline year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Coherus Oncology, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $368,124,000 -$44,709,000 -11% 31 Dec 2025 10-K 09 Mar 2026 2025 FY
Q4 2024 $412,833,000 -$10,552,000 -2.5% 31 Dec 2024 10-K 09 Mar 2026 2025 FY
Q4 2023 $423,385,000 +$85,612,000 +25% 31 Dec 2023 8-K 13 Nov 2025
Q4 2022 $337,773,000 +$64,429,000 +24% 31 Dec 2022 10-K 15 Mar 2024 2023 FY
Q4 2021 $273,344,000 +$72,419,000 +36% 31 Dec 2021 10-K 06 Mar 2023 2022 FY
Q4 2020 $200,925,000 -$22,733,000 -10% 31 Dec 2020 10-K 23 Feb 2022 2021 FY
Q4 2019 $223,658,000 -$13,400,000 -5.7% 31 Dec 2019 10-K 25 Feb 2021 2020 FY
Q4 2018 $237,058,000 +$54,643,000 +30% 31 Dec 2018 10-K 27 Feb 2020 2019 FY
Q4 2017 $182,415,000 +$4,614,000 +2.6% 31 Dec 2017 10-K 28 Feb 2019 2018 FY
Q4 2016 $177,801,000 +$43,016,000 +32% 31 Dec 2016 10-K 08 Mar 2018 2017 FY
Q4 2015 $134,785,000 +$79,198,000 +142% 31 Dec 2015 10-K 14 Mar 2017 2016 FY
Q4 2014 $55,587,000 +$22,093,000 +66% 31 Dec 2014 10-K 29 Feb 2016 2015 FY
Q4 2013 $33,494,000 31 Dec 2013 10-K 23 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.